Search results for "tumors"

Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio

Novartis to Buy UK Biotech Myricx for Up to $1.5 Billion, Boosting ADC Portfolio

Novartis is significantly expanding its oncology portfolio after securing an antibody-drug conjugate technology designed to deliver potent anticancer...
Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer

Qurient’s Mocaciclib Opens New Combination Frontiers for Hard-to-Treat Breast Cancer

Qurient announced on June 29 that it presented key clinical data highlighting the mechanistic advantages of its CDK7-inhibiting oncology candidate,...
Born to Age Faster? How Accelerated Biological Aging Drives Rising Cancer Risk in Younger Generations

Born to Age Faster? How Accelerated Biological Aging Drives Rising Cancer Risk in Younger Generations

As cancer incidence inexplicably rises among younger adults worldwide, a pivotal new study suggests an unsettling...
Radioembolization Extends Survival in Select Patients with Advanced Liver Cancer, Study Finds

Radioembolization Extends Survival in Select Patients with Advanced Liver Cancer, Study Finds

Hearing a doctor say that “the cancer has invaded the portal vein” can be deeply overwhelming for patients with liver...
When High Blood Sugar Won’t Go Away: The Overlooked Warning Sign of Pancreatic Cancer

When High Blood Sugar Won’t Go Away: The Overlooked Warning Sign of Pancreatic Cancer

Pancreatic cancer is notoriously difficult to detect in its early stages because symptoms typically manifest late in...
Mapping Cancer’s Footprint: Specialized PET/CT Scans Pinpoint Metastasis and Recurrence

Mapping Cancer’s Footprint: Specialized PET/CT Scans Pinpoint Metastasis and Recurrence

Following a cancer diagnosis, patients and their families almost invariably ask the same urgent question: “How far has...
From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

From Bludgeon to Scalpel: ASCO 2026 Signals Oncology’s Shift From ‘Strong Chemo’ to ‘Right Chemo’

The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological...
Shifting Trends in Stomach Cancer: Why Young Women Face a Stealthier Threat

Shifting Trends in Stomach Cancer: Why Young Women Face a Stealthier Threat

Data released by South Korea's Central Cancer Registry show that the nation recorded 28,943 new stomach cancer cases...
Celltrion Advances Next-Generation Immuno-Oncology Candidate with Strong Preclinical Results

Celltrion Advances Next-Generation Immuno-Oncology Candidate with Strong Preclinical Results

Celltrion has announced promising preclinical data for its investigational immuno-oncology candidate, CT-P72/ABP-102,...
Asan Medical Center Breaks Ground on Korea’s Largest Heavy-Ion Cancer Therapy Center

Asan Medical Center Breaks Ground on Korea’s Largest Heavy-Ion Cancer Therapy Center

Asan Medical Center is bringing heavy-ion therapy—one of the world's most advanced weapons against cancer—to its...